¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)
¼¶±ð: ×ܰæÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-25   

Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)

Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ nV`n=x  
GJTKqr|1O  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© \iN3/J4  
aTi2=HL=S  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© !+bLh W`  
3K)12x$.K  
1.Co-stimulators (or co-stimulating molecules) %K9pnq/T^  
0EWov~Y?  
2.NK-kB }uZtAH|  
W^(:\IvV  
3.Immunoglobulin superfamily aC!e#(q  
UQ X.  
4.antigen-presenting cell (APC) LUPh!)8  
)Bz2-|\  
5.death domain <R;t>~8x  
wP|Amn+;  
6.CCR and CXCR CIt%7 \c  
g$^:2MT"aQ  
7.Lectin (or mitogen) E*B6 k!:  
-(oFO'Lbg  
8.Clusters of differentiation, CD) e7O9q8b  
 c6f=r  
9.B7 family T'W@fif  
 AhyV  
10.Cytotoxic T lymphocyte, CTL) z~m{'O `  
l* a p$1'  
11.IL-15 and IL-15 receptor (IL-15R) Rfx}[!<{N  
}CM</  
12.MHC restriction `)aIFAW  
t| cL!  
13.Affinity-chromatography qN=l$_UD  
7u=R5  
14.Cyctosprin A, CsA &^7^7:Y=?  
swTur  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) S|K#lL  
ahUc ;S:v#  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© G u4mP  
c e\| eN[  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 [Yyb)Qf  
F,.dC&B  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ |19 zjhl  
} \?]uNH  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ ~Qm<w3oy  
}od5kK;  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© {Q(R#$)5+  
s#* DY  
ÃâÒßѧרҵ£º X4$86  
U3 tA"X.K  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ \s@7pM=(  
gLzQM3{X9  
Ïû»¯ÄÚ¿Æ£º 7i##g,  
*p.70,5,  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ +#RqQ8 \  
JBMJR  
ѪҺ²¡Ñ§×¨Òµ£º [9H986=  
YsA.,   
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
4+6=? ÕýÈ·´ð°¸:10
°´"Ctrl+Enter"Ö±½ÓÌá½»